Caption Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.4K Buy
+800
New +$12.4K ﹤0.01% 1580
2024
Q3
Sell
-150,000
Closed -$285K 1249
2024
Q2
$285K Hold
150,000
﹤0.01% 907
2024
Q1
$426K Buy
+150,000
New +$1.96M 0.01% 906
2023
Q4
Sell
-227,800
Closed -$4.17M 1318
2023
Q3
$4.17M Buy
227,800
+53,800
+31% +$1.14M 0.06% 365
2023
Q2
$3.75M Buy
174,000
+159,000
+1,060% +$4.29M 0.07% 352
2023
Q1
$440K Buy
+15,000
New +$521K 0.01% 812
2022
Q4
Sell
-145,000
Closed -$4.08M 1257
2022
Q3
$4.08M Buy
145,000
+95,000
+190% +$2.37M 0.06% 410
2022
Q2
$963K Buy
+50,000
New +$594K 0.01% 891

Other funds holding AMLX

Caption Management's AMLX Position: Q2 2026 in Review

Caption Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 174 shares worth $3.13K. The stake represents ﹤0.01% of the portfolio and ranks #1590 among its holdings. This is a return to the name: Caption Management previously reported a position in AMLX as recently as Q2 2024.

Caption Management first reported a position in AMLX in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.63M in Q3 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Caption Management held 174 shares of Amylyx Pharmaceuticals worth $3.13K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Caption Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1590 holding.
  • Caption Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
  • Caption Management's Amylyx Pharmaceuticals position peaked at $1.63M in Q3 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.